Transcriptional modulation of β-Secretase ameliorates amyloid pathology and cognitive deficits in Alzheimer’s disease models

Abstract

its pleiotropic pharmacology, CHX should be regarded here as a nonselective pharmacological probe rather than a repurposing-ready AD therapeutic. That said, the effect does not appear to be simply broad, nonspeci fi c suppression. Components of the γ -secretase complex were unchanged by CHX, and the reduction in gliosis and neuroin fl ammatory markers is more readily explained as a downstream consequence of the lower amyloid burden than as a separate off-target effect. This study has several limitations. Our analysis focused on A β -associated pathology and did not extend to Tau phosphorylation, Tau aggregation